In the latest trading session, 2.05 million Pyxis Oncology Inc (NASDAQ:PYXS) shares changed hands as the company’s beta touched 1.11. With the company’s most recent per share price at $1.25 changing hands around $0.05 or 3.75% at last look, the market valuation stands at $74.04M. PYXS’s current price is a discount, trading about -448.0% off its 52-week high of $6.85. The share price had its 52-week low at $1.19, which suggests the last value was 4.8% up since then.
Analysts gave the Pyxis Oncology Inc (PYXS) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.25. If we narrow down to specifics, the data shows that 0 out of 2 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 1 recommended PYXS as a Hold, 1 felt it is a Buy and 0 rated the stock as Underweight. Pyxis Oncology Inc’s EPS for the current quarter is expected to be -0.33.
Pyxis Oncology Inc (NASDAQ:PYXS) trade information
Instantly PYXS is in green as seen in intraday trades today. With action -7.78%, the performance over the past five days has been red. The company’s shares are showing year-to-date downside of -20.19%, with the 5-day performance at -7.78% in the red. However, in the 30-day time frame, Pyxis Oncology Inc (NASDAQ:PYXS) is -20.70% down.
The consensus price target for the stock as assigned by Wall Street analysts is 10, meaning bulls need an upside of 87.5% from its recent market value. According to analyst projections, PYXS’s forecast low is 7 with 10 as the target high. To hit the forecast high, the stock’s price needs a -700.0% plunge from its current level, while the stock would need to soar -460.0% for it to hit the projected low.
Pyxis Oncology Inc (PYXS) estimates and forecasts
According to analysts, the company will likely register a growth in its current quarter sales, forecast at 0.00%. The estimates for the next quarter sales put growth at -100.00%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -118.72%. The 2025 estimates are for Pyxis Oncology Inc earnings to increase by 40.99%, but the outlook for the next 5-year period is at 12.25% per year.
Pyxis Oncology Inc (NASDAQ:PYXS)’s Major holders
LAURION CAPITAL MANAGEMENT LP holds the second largest percentage of outstanding shares, with 6.3826% or 3.86 million shares worth $12.78 million as of 2024-06-30.
Among Mutual Funds, the top two as of Nov 30, 2024 were iShares Russell 2000 ETF and Vanguard Total Stock Market Index Fund. With 1.34 shares estimated at $1.66 million under it, the former controlled 2.25% of total outstanding shares. On the other hand, Vanguard Total Stock Market Index Fund held about 2.18% of the shares, roughly 1.29 shares worth around $1.61 million.
